| |
||
|
Catalogue Number |
Product | Order number / Unit |
| |
||
| 9716 | DOTA-NOC acetate (GMP) |
9716.0000.06: 60 μg per vial 9716.0000.10: 100 μg per vial 9716.0000.25: 250 μg per vial 9716.0001: 1 mg per vial Please inquire for customized filling and bulk quantities.
|
|
Precursor for radiolabelled DOTA-NOC
Ligand for somatostatin receptors |
||
| Manufactured according to GMP requirements for APIs for use in clinical trials (ICH Q7 chapter 19) | ||
| Molar Mass: 1455.7 | ||
| C69H94N14O17S2 | ||
| [619300-53-7] (net peptide) | ||
| Colourless to off-white solid packaged in plastic vials | ||
|
Purity: > 98 % (9716.0001) > 97 % (9716.0000.06 9716.0000.10 9716.0000.25) |
||
|
Certificates:
CoA with ESI-MS (identity); HPLC (purity); GC (residual solvents, acetate content, water content); heavy metal content (ICP-MS) |
||
|
Chemical Name: Sequence: DOTA-D-Phe-Cys-Nal-D-Trp-Lys-Thr-Cys-Thr(ol), cyclic disulfide Cys2,7 DOTA = N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]- Nal = 3-(1-naphthalenyl )-L-alanyl Supplied as acetate salt |
||
|
Synonymes: DOTA-[Nal3]-octreotide; CA index name: L-Cysteinamide, N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-phenylalanyl-L-cysteinyl-3-(1-naphthalenyl)- L-alanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2→7)-disulfide |
||
|
Literature: Same as product number 9712. |
||
| date of product catalogue issue: 10 May 2017 | ||